Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IART 
Integra LifeSciences Holdings (IART)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: IART (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $16.12
1 Year Target Price $16.12
| 2 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 2 | Sell |
| 2 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 16.12 |
Price to earnings Ratio - | 1Y Target Price 16.12 | ||
Volume (30-day avg) 12 | Beta 1.17 | 52 Weeks Range 11.06 - 32.66 | Updated Date 07/10/2025 |
52 Weeks Range 11.06 - 32.66 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -1.78% | Operating Margin (TTM) 8.23% |
Management Effectiveness
Return on Assets (TTM) 2.66% | Return on Equity (TTM) -1.86% |
Valuation
Trailing PE - | Forward PE 5.83 | Enterprise Value 2759787175 | Price to Sales(TTM) 0.62 |
Enterprise Value 2759787175 | Price to Sales(TTM) 0.62 | ||
Enterprise Value to Revenue 1.7 | Enterprise Value to EBITDA 15.31 | Shares Outstanding 77712304 | Shares Floating 61777372 |
Shares Outstanding 77712304 | Shares Floating 61777372 | ||
Percent Insiders 14.22 | Percent Institutions 96.47 |
Upturn AI SWOT
Integra LifeSciences Holdings
Company Overview
History and Background
Integra LifeSciences Holdings was founded in 1989. It has grown through acquisitions and organic development to become a leading provider of regenerative medicine products and surgical instruments.
Core Business Areas
- Codman Specialty Surgical (CSS): Focuses on neurosurgery, dural repair, and advanced energy products.
- Tissue Technologies: Deals with skin and wound reconstruction, tendon repair, and nerve repair products.
Leadership and Structure
Jan De Witte serves as the President and CEO. The company has a typical corporate structure with functional departments reporting to the CEO.
Top Products and Market Share
Key Offerings
- DuraGen: A dural regeneration matrix used in neurosurgery. Market share is significant in dural repair. Competitors include Baxter and Medtronic.
- Integra Bilayer Matrix Wound Dressing: Used for wound healing and skin reconstruction. Competitors include Smith & Nephew and Molnlycke.
Market Dynamics
Industry Overview
The regenerative medicine and surgical instrument market is growing due to an aging population and increasing demand for advanced medical technologies.
Positioning
Integra LifeSciences Holdings is a key player in the regenerative medicine and neurosurgery segments, known for its innovative products and strong market presence.
Total Addressable Market (TAM)
The TAM for Integra's segments is estimated to be over $10 billion. Integra is positioned to capture a significant share of this market through product innovation and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Strong Brand Recognition
- Diverse Product Portfolio
- Established Distribution Network
- Focus on Innovation
Weaknesses
- High Debt Levels
- Dependence on Acquisitions
- Integration Challenges
- Exposure to Regulatory Risks
Opportunities
- Expanding into Emerging Markets
- Developing New Products
- Acquiring Complementary Businesses
- Increasing Adoption of Regenerative Medicine
Threats
- Intense Competition
- Pricing Pressures
- Product Liability Claims
- Economic Downturns
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Stryker (SYK)
- Johnson & Johnson (JNJ)
Competitive Landscape
Integra LifeSciences Holdings faces stiff competition from larger medical device companies. Its competitive advantage lies in its specialized product portfolio and strong brand reputation.
Major Acquisitions
Acquired Amnio Technology Group
- Year: 2021
- Acquisition Price (USD millions): 14
- Strategic Rationale: Expanded portfolio of advanced wound care products
Acquired Acell, Inc.
- Year: 2017
- Acquisition Price (USD millions): 300
- Strategic Rationale: Accelerated growth in advanced wound care.
Growth Trajectory and Initiatives
Historical Growth: Integra LifeSciences Holdings has grown through a combination of organic growth and acquisitions.
Future Projections: Analysts project moderate revenue growth and improved profitability for Integra LifeSciences Holdings in the coming years.
Recent Initiatives: Integra LifeSciences Holdings is focused on expanding its product portfolio through R&D and strategic acquisitions.
Summary
Integra LifeSciences Holdings has a strong position in regenerative medicine and surgical instruments but faces financial challenges, including high debt and negative net income. The company's strengths lie in its product portfolio and innovation, while it needs to address profitability and cash flow. Future growth depends on successful product development and acquisitions. Regulatory changes and increasing competition need to be monitored.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Integra LifeSciences Holdings
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 1995-08-16 | President, CEO & Director Ms. Mojdeh Poul | ||
Sector Healthcare | Industry Medical Devices | Full time employees 4396 | Website https://www.integralife.com |
Full time employees 4396 | Website https://www.integralife.com | ||
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company addresses the needs of plastic, and reconstructive and general surgeons focused on the treatment of acute wounds, such as burns and chronic wounds, including diabetic foot ulcers; and provides surgical tissue repair products for hernia, tendon, peripheral nerve repair, and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. Further, it is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.